spiperone has been researched along with Basal Ganglia Diseases in 4 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with risperidone, 6 mg/day, is likely to induce unnecessarily high D2 receptor occupancy, with a consequent risk of extrapyramidal side effects." | 2.69 | Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. ( Eriksson, B; Farde, L; Halldin, C; Nyberg, S; Oxenstierna, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borison, RL | 1 |
| Hitri, A | 1 |
| Blowers, AJ | 1 |
| Diamond, BI | 1 |
| Allen, RM | 1 |
| Nyberg, S | 1 |
| Eriksson, B | 1 |
| Oxenstierna, G | 1 |
| Halldin, C | 1 |
| Farde, L | 1 |
| Krska, J | 1 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Soni, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for spiperone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Antipsychotic drug action: clinical, biochemical, and pharmacological evidence for site specificity of action.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Binding Sites; Caudate Nucleus; Extrapyramida | 1983 |
Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology.
Topics: Amantadine; Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Binding, Competitive | 1983 |
1 trial available for spiperone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Dose-Response Rela | 1999 |
1 other study available for spiperone and Basal Ganglia Diseases
| Article | Year |
|---|---|
Radio receptor assay of serum neuroleptic levels in psychiatric patients.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Halo | 1986 |